Castration-Resistant Prostate Cancer Cells Are Addicted to the High Activity of Cyclin-Dependent Kinase 2

Scientists developed a CDK2 inhibitor-resistant CRPC model and performed a rational compound screen to assess which of the currently used anti-CRPC treatments could augment CDK2 therapy-response.